Login to Your Account


Wins EMA and FDA approvals
LONDON – The first PARP (poly ADP-ribose polymerase) inhibitor is poised for market after Astrazeneca plc's Lynparza (olaparib) cleared the final approval hurdle in Europe and – late Friday – in the U.S. The approvals mark a remarkable turnaroun. more »

Our Habitat for All Things Science
Osteoporosis drugs could prevent, treat HER-driven cancers

Bisphosphonates have been used since the early 1990s in two indications. They are most famous as osteoporosis drugs, where even off-patent, Fosamax (alendronate sodium, Merck & Co. Inc.) – only one of several bisphosphonates – raked in more than $700 million in sales in 2013, according to Thomson Reuters Cortellis.

They are also used in cancer "primarily to prevent bone metastases and their consequences, but never for the cancer itself," Mone Zaidi told BioWorld Today.

READ MORE »